Panel Recommends Listing 9 Substances in Carcinogen Report

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 3
Volume 9
Issue 3

ARLINGTON, Va-A scientific panel has recommended listing nine substances as either “known” or “reasonably anticipated” to be human carcinogens. If upheld after review, the substances will be listed in the 10th “Report on

 ARLINGTON, Va—A scientific panel has recommended listing nine substances as either “known” or “reasonably anticipated” to be human carcinogens. If upheld after review, the substances will be listed in the 10th “Report on Carcinogens,” prepared by the National Toxicology Program (NTP) and scheduled for publication in 2002.

The panel voted to upgrade beryllium and beryllium compounds (substances used in fiber optics, aerospace, and other industrial applications) from “reasonably anticipated” to “known” human carcinogens. They recommended listing vinyl bromide and vinyl fluoride as “known” human carcinogens. Vinyl bromide’s primary use is in making flame-retardant synthetic fibers. Vinyl fluoride is a chemical used in making polyvinylfluoride, which is used in the plastics industry.

The panel also recommended listing two other chemicals used in make products flame resistant as “reasonable anticipated” to be human carcinogens: 2,2-bis-(bromomethyl)l-1,3-propanediol used in unsaturated polyester resins, molded products, and rigid polyurethane foam, and 2,3-dibromo-1-propanol, also found in pesticides and drug preparations.

Three other substances were cited as “reasonably anticipated” to be human carcinogens: dimethylbenzidine dyes used in some textiles and plastics; IQ, found in cooked meat and fish; and styrene-7,8-oxide, use in preparing fragrances.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content